According to Zhitong Finance App, Yi Ming Pharmaceutical (002826.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 360 million yuan, up 15.47% year on year; net profit attributable to shareholders of listed companies was 666.797 million yuan, up 77.54% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 41.6428 million yuan, up 66.42% year on year; basic earnings per share were 0.36 yuan.

In the first half of 2026, the company implemented a two-tier parallel business development strategy to coordinate stock business protection and incremental business development. In terms of stock business, the company relies on lean production system construction to continuously strengthen the overall management of the supply chain, consolidate the cost competitive advantage of existing products, ensure a stable market share of the stock business, and consolidate the company's basic operating cash flow; in terms of incremental business, the company focuses on medical needs that have not been fully met, such as special groups such as elderly patients with diabetes and hepatic and renal insufficiency, and conducts market research and resource investment around the clinical characteristics of target patient groups to cultivate differentiated businesses and new value growth points.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.